


Preclinical-stage, cell and gene therapy biotech

Establishment: Oct. 2020, Tokyo, Japan

Series-A: **\$7.7M**, Grant: up to **\$19M** (Non-dilutive funding) as of Nov. 2024, \$1=150yen Technology: **Ex vivo expansion of functional Hematopoietic Stem Cell (LT-HSC)**


Celaid's Media



High Expansion of LT-HSC, important source for all blood cells (Compared to competitor)

- No gene modification
- Low cost, high productivity (Use chemical compounds)

Problem / Solution for Cell and Gene therapy




Solution: Selective HSC expansion		
Cell co	unt Celaid	10000
35,000	LT-HSC:	
30,000	CD201+CD45RA- in CD34+Lin-	000
25,000	Furnand -	
20,000	Expand HSC	
15,000	Competitor	
10,000	Control (Commercial research medium)	
5,000		
0		
Ū	7 10 12 14 17 Culture period (days)	



Platform-available for partnering

· Celaid's platform technology can be applied to several cell therapy products

Several collaborations are proceeding under MTA or co-research agreement



Wholly-owned pipeline

• Celaid has 4 pipelines, 1st lead pipeline under development in the US



Allo expanded-HSC product Pediatric hematological rare disease



Allo expanded-HSC product

Auto expanded-HSC product

Allo expanded-HSC product – off the shelf Multiple Myeloma

(blood cancer)

Leukemia

(blood cancer)



Our Ask
Find Investors for Series B fundraise \$10M (2025/6)
Find collaboration partners for Pipeline / Platform